| Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer (NCT02566772) | Taiho Oncology, Inc. | 2016-03-01 |
| Optimizing Abiraterone Therapy (NCT02426333) | Radboud University Medical Center | 2016-01-01 |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers (NCT02655822) | Corvus Pharmaceuticals, Inc. | 2016-01-01 |
| Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (NCT02471469) | Radboud University Medical Center | 2015-10-01 |
| European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT02495974) | Astellas Pharma Europe Ltd. | 2015-09-08 |
| A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy (NCT02405858) | Janssen Pharmaceutical K.K. | 2015-04-10 |
| Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer (NCT02424448) | The Christie NHS Foundation Trust | 2014-12-01 |
| A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone (NCT02288247) | Astellas Pharma Europe Ltd. | 2014-12-01 |
| Sequencing Abiraterone and Enzalutamide in mCRPC (NCT02125357) | British Columbia Cancer Agency | 2014-09-01 |
| Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT02141438) | Bayer | 2014-08-20 |
| Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer (NCT04056754) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2014-07-16 |
| A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT02123758) | Aragon Pharmaceuticals, Inc. | 2014-07-09 |
| Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (NCT02111577) | SOTIO a.s. | 2014-05-26 |
| A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer (NCT02116582) | Astellas Pharma Europe B.V. | 2014-05-23 |
| Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer (NCT02044354) | Gustave Roussy, Cancer Campus, Grand Paris | 2014-05-22 |
| Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment (NCT02047253) | University of Alabama at Birmingham | 2014-04-01 |
| Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. (NCT01972217) | AstraZeneca | 2014-04-01 |
| Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients (NCT02091531) | Memorial Sloan Kettering Cancer Center | 2014-03-01 |
| Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer (NCT01942837) | Dana-Farber Cancer Institute | 2013-09-13 |
| A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01663415) | Astellas Pharma Global Development, Inc. | 2012-08-01 |
| A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (NCT01650194) | Astellas Pharma Global Development, Inc. | 2012-07-09 |
| Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer (NCT01594918) | Rahul Aggarwal | 2012-06-01 |
| A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer (NCT01541007) | Jeffrey Yachnin M.D., PhD. | 2012-04-01 |
| A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate (NCT01517802) | Janssen Research & Development, LLC | 2012-03-28 |
| A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. (NCT00428220) | Pfizer | 2007-07-01 |
| Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination) (NCT05401214) | Janssen Research & Development, LLC | |
| Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (NCT01606982) | Astellas Pharma Global Development, Inc. | |
| Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) (NCT05650476) | Pfizer | |